TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03936816

Intervention type: OTHER
Intervention: GBS vaginal double swab
Description: The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).

Intervention type: OTHER
Intervention: GBS vaginal double swab
Description: The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
Study: NCT02200471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer
Study: NCT01463865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
Study: NCT01003080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquamantys Device
Description: The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment for hemostasis during a total knee arthroplasty.
Description: The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device.
Study: NCT01173341

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
Study: NCT00152126

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan, Melphalan
Description: Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
Study: NCT04019002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Pyruvate
Description: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
Study: NCT04234776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suicide risk
Description: MADRS (10) and HAM-D (3)
Study: NCT01173341

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.

Intervention type: OTHER
Intervention: Blood Collection
Description: Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.

Intervention type: OTHER
Intervention: Blood Collection
Description: Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.

Intervention type: OTHER
Intervention: Blood Collection
Description: Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.

Intervention type: OTHER
Intervention: Symptoms Questionnaire
Description: Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.

Intervention type: OTHER
Intervention: Symptoms Questionnaire
Description: Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.

Intervention type: OTHER
Intervention: Symptoms Questionnaire
Description: Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
Study: NCT01977079

Intervention type: OTHER
Group type: OTHER
Intervention: procalcitonin

Intervention type: OTHER
Group type: OTHER
Intervention: procalcitonin
Study: NCT02612961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3mL of normal saline from the pink sodium chloride bullet

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator of 3mL normal saline
Study: NCT01804322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized educational plan
Description: The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care according to the participating Epilepsy Centers
Study: NCT00848549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
Study: NCT03779035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250mg/m2
Study: NCT02860806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
Study: NCT04234776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suicide risk
Description: MADRS (10) and HAM-D (3)
Study: NCT00489281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
Study: NCT04234776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depression thoughts
Description: EPD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression thoughts
Description: EPD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life and disability
Description: Quality of life and disability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life and disability
Description: Quality of life and disability

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical and epidemiological factors
Description: Variables and categories

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and epidemiological factors
Description: Variables and categories

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Safety of ketamine IM
Description: Vital signs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safety of ketamine IM
Description: Vital signs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tolerability of ketamine IM
Description: UKU-SERS, YOUNG, CADSS and BPRS-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tolerability of ketamine IM
Description: UKU-SERS, YOUNG, CADSS and BPRS-12.
Study: NCT00839241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bellovac ABT
Description: Bellovac ABT (autologous blood)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic Blood Transfusion
Description: Transfusion of allogenic (bank) blood.
Study: NCT03668288

Intervention type: OTHER
Intervention: Data record and questionnaires passation
Description: Data record and questionnaires passation (SF36)
Study: NCT02754999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: As needed (PRN) infusions of 500 mL of SANGUINATE
Study: NCT03014973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-prostatic concentration of sexual steroids
Study: NCT04019002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Pyruvate
Description: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Pyruvate
Description: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
Study: NCT02860806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: 3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of matching placebo.
Study: NCT00489281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Description: An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
Study: NCT03014973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-prostatic concentration of sexual steroids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-rectal biopsy
Study: NCT03645772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: 12-week progressive training intervention
Study: NCT03014973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-rectal biopsy
Study: NCT03645772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: 12-week progressive training intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: 12-week progressive training intervention
Study: NCT01268813

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Breath analysis and blood analysis
Description: Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath analysis and blood analysis
Description: Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
Study: NCT01348425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Longer Zilver PTX Stents
Description: Treatment with at least one 100 mm or longer Zilver PTX stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shorter Zilver PTX Stents
Description: Treatment with Zilver PTX stents 80 mm or shorter only
Study: NCT03321214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Sensor Dose-Finding Intervention
Description: Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Sensor Dose-Finding Intervention
Description: Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Sensor Dose-Finding Intervention
Description: Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants.
Study: NCT03522272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning
Description: Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic cleaning
Description: Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional denture hygiene
Description: Mechanical cleaning of denture with a soft toothbrush and liquid detergent
Study: NCT01892618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: 13-valent pneumococcal conjugated vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Description: 23-valent pneumococcal polysaccharide vaccine
Study: NCT00702156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
Study: NCT04198103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transperineal Focal Laser Ablation (TPLA)
Description: The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
Study: NCT02940717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita suprinity
Description: New glass ceramic material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emax CAD
Description: standard etchable glass ceramic used for laminate venneers
Study: NCT00681538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Study: NCT04105244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training©
Description: The intervention includes self-help and help-seeking skills.
Study: NCT01745991

Intervention type: DEVICE
Intervention: CoSeal spray
Study: NCT00975195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol xinafoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo matched for fluticasone propionate
Study: NCT00780169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib + FOLFIRI
Description: escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1
Study: NCT00394290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Pressure
Description: Nighttime continuous positive pressure device, to be used every day
Study: NCT00634959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 100 mg oral tablet once daily while fasted on Days 1-10
Study: NCT00489281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant
Description: An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation - 200
Description: 200 centigray (cGy) in one fraction on Day -1.
Study: NCT00634959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 300 mg oral tablet once daily while fasted on Days 1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet on Days 1-10 (fed and fasted)
Study: NCT00717262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1001
Description: HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo capsules administered once a day, orally, for 14 days.